PolyPid Ltd. Ordinary Shares PYPD
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:53:01.003Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:51:52.527919009Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:53:00.600202+00:00
PolyPid Ltd. Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.80 | 232.8% | 51.4% | 5.20 | 223.3% | 26.7% |
| 25Δ | 8.78 | 187.8% | 36.2% | 5.49 | 220.1% | 24.3% |
| 30Δ | 7.77 | 142.7% | 21.0% | 5.78 | 217.0% | 21.8% |
| 35Δ | 6.07 | 213.9% | 19.4% | |||
| 40Δ | 6.36 | 210.7% | 17.0% | |||
| 45Δ | 6.66 | 207.6% | 14.6% | |||
| 50Δ | 6.95 | 204.5% | 12.1% | |||
| 55Δ | 7.24 | 201.3% | 9.7% | |||
| 60Δ | ||||||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 9.80
- IV
- 232.8%
- B/E move
- 51.4%
- Pseudo strike
- 5.20
- IV
- 223.3%
- B/E move
- 26.7%
25Δ
- Pseudo strike
- 8.78
- IV
- 187.8%
- B/E move
- 36.2%
- Pseudo strike
- 5.49
- IV
- 220.1%
- B/E move
- 24.3%
30Δ
- Pseudo strike
- 7.77
- IV
- 142.7%
- B/E move
- 21.0%
- Pseudo strike
- 5.78
- IV
- 217.0%
- B/E move
- 21.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.07
- IV
- 213.9%
- B/E move
- 19.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.36
- IV
- 210.7%
- B/E move
- 17.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.66
- IV
- 207.6%
- B/E move
- 14.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.95
- IV
- 204.5%
- B/E move
- 12.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.24
- IV
- 201.3%
- B/E move
- 9.7%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 133.88% | |
| 130.24% | |
| 145.64% | |
| 176.79% | |
| 162.76% | |
| 160.87% | |
| 162.04% |
Biotechnology
PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in…
More →RANI
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the…
More →RAPP
Description unavailable
More →RARE
Description unavailable
More →